Ever since the passage of the Inflation Reduction Act (IRA), which gave the Centers for Medicare and Medicaid Services (CMS) the ability to negotiate maximum fair prices (MFP) for a selected group of ...

In the wake of the Food and Drug Administration’s (FDA’s) controversial decision to approve aducanumab for Alzheimer’s disease, how will, and how should, Medicare respond? We propose a coverage with ...

Phase 3 of the Centers for Medicare & Medicaid Services’ Requirements for Participation for nursing facilities will go into effect on November 28. But those who have not yet read CMS’s recent ...